A Dose-Finding Study of MM-120 for the Treatment of Anxiety Symptoms
Status:
Recruiting
Trial end date:
2023-11-30
Target enrollment:
Participant gender:
Summary
This is a Phase 2, multi-center, randomized, double-blind, parallel-group, dose-finding study
to assess the effect of 4 doses of MM-120 (25, 50, 100 or 200 μg freebase-equivalent) for the
treatment of anxiety symptoms in subjects diagnosed with generalized anxiety disorder (GAD).